SUMMARY: Although tick-borne rickettsiosis is endemic in Greece, until recently, human samples arriving at the National Reference Centre under suspicion of rickettsial infection were routinely tested only for Rickettsia typhi and R. conorii. However, identification of additional rickettsia species in ticks prompted revision of the protocol in 2010. Until that year, all human samples received by the laboratory were tested for antibodies against R. conorii and R. typhi only. Now, tests for R. slovaca, R. felis, and R. mongolotimonae are all included in routine analysis. The current description of a human R. slovaca case is possible as a result of these changes in routine testing.
A 42-year-old woman from the island of Corfu, Greece, was hospitalized in November 2011 for highgrade fever (up to 39.59 C) and malaise. The patient had visited a physician 2 days before admission and was administered clarithromycin (500 mg twice daily) with no improvement. Routine blood tests revealed moderately Table 1 ). The patient reported living in a rural area of the island, but no contact with animals. A careful clinical examination did not reveal any signs of a tick bite such as an eschar or lymphadenopathy; however, 2 days after admission the patient developed a maculopapular rash on the face, thorax, and extremities, including the palms and soles. In addition, she complained of myalgia, arthralgia, and a non-productive cough. On clinical examination, conjunctivitis was also noted. A summary of the patient's clinical data is shown in Table 2 . New blood tests 4 days after admission showed mild leucopenia (WBC: 3.3 × 10 6 /L) and further increase of transaminase levels (AST: 210 IU/L, ALT: 243 IU/L, gGT: 300 IU/L, ALP: 296 IU/L, LDH: 829 IU/L) ( Table 1 ). The patient received doxycycline (100 mg twice daily for 7 days) as soon as the rash developed. One week later, she became afebrile and the rash faded, although malaise persisted. The patient returned home and at one month follow-up there was complete resolution of symptoms and normalization of blood tests.
Blood samples, whole and serum, were drawn 10 days after hospitalization. DNA was extracted using the QIAamp DNA blood mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions.
Real-time PCR targeting the glta gene of Rickettsia spp. was performed as previously described (1). As confirmation, the ompA gene was also amplified by PCR (2). Additionally, real-time PCR was used to test for the DNA of Anaplasma phagocytophilum, Borrelia spp., and Bartonella spp. IFA was used to test serum for presence of antibodies against Rickettsia spp., using a slide that tested for R. conorii, R. siberica, R. slovaca, R. felis, R. massiliae, and R. typhi as individual antigens (Fuller laboratories, Fullerton, CA, USA). IFA was also conducted for antibodies against A. phagocytophilum (Focus Diagnostics, Cypress, CA, USA), B. henselae, and B. quintana (Focus Diagnostics). Western blot analysis was used to test for antibodies against Borrelia spp. (Mikrogen Diagnostik, Neuried, Germany). All analyses were performed at the Regional Laboratory of Public Health of Crete, Greece.
IgM antibodies against R. slovaca were detected (1/512). No antibodies were detected against any other Rickettsia spp., Borrelia spp., Bartonella spp., or A. phagocytophilum. Both real-time PCR and PCR targeting the ompA gene of Rickettsia spp. gave positive results. All real-time PCR analyses for other pathogens were negative. The PCR product corresponding to the ompA gene was sequenced, revealing a 100z similarity to an already R. slovaca published sequence (U43808). This sequence is also identical to a strain detected in ticks in Northern Greece (3).
Tick-borne rickettsiosis is endemic in Greece; various Rickettsia species have been identified in humans and ticks in the past 10 years (4-10). Recently, R. slovaca infection was detected for the first time in ticks in Northern Greece (3).
The pathogen was first isolated in 1968 from Dermacentor marginatus in Slovakia (11) . The first proven case of infection was reported in France in 1997 (12) . In recent years, human R. slovaca infection has been reported with increasing frequency in France, Hungary, Spain, Italy, Germany, and Bulgaria (13) (14) (15) (16) . Clinical signs of infection consist of a skin lesion (eschar) at the site of inoculation, usually the scalp, and regional lymphadenopathy. This recently described syndrome is 
known as SENLAT (scalp eschar associated with neck lymphadenopathy after a tick bite), or TIBOLA/ DEBONEL (tick-borne lymphadenopathy/Dermacentor-borne necrosis, erythema, lymphadenopathy). Often caused by R. slovaca, it is characterized as a local infection controlled by the immune system, which is neither pathogen-nor vector-specific (17, 18) . Fever and rash are not as common as in other rickettsial infections. In the current case, the clinical presentation included high-grade fever and a maculopapular rash, whereas other main signs (eschar, lymphadenopathy) were missing. There are previous reports of R. slovaca infections without skin lesions (19) , or that present a maculopapular rash (14) , indicating that R. slovaca can be associated with other clinical forms. Moreover, our patient presented with moderately elevated transaminase levels, indicating hepatic involvement in the course of infection. To our knowledge, this is the first reported case of human infection by R. slovaca in Greece. The case was also associated with atypical clinical manifestations. Clinicians should bear in mind the possibility of infection by pathogens other than the well-known R. conorii and R. typhi.
